AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: ARDX
Report Date: 2026-08-07
Full Report: https://amaly.io/stock/ARDX

EXECUTIVE SUMMARY
------------------
Compliance Status: NON_COMPLIANT
Quality Rating: B
Description: Ardelyx, Inc. (ARDX) is a biopharmaceutical company focused on innovative therapies for gastrointestinal and kidney diseases. This report evaluates its Shariah compliance based on financial ratios, business activities, index inclusion, and multi-perspective analysis. While financial screens indicate compliance with key thresholds, the absence of inclusion in major Shariah indices results in an overall non-compliant status. Purification is required for minor interest income, and ESG factors align well with Islamic principles. Investors should monitor for potential index eligibility as the company grows.

Primary Compliance Concerns:
- Absence of inclusion in major Shariah indices due to market cap and liquidity criteria
- Interest income ratio of 4.82%, requiring purification

Purification Requirement: 4.82%
Index Inclusion: Not included in S&P Dow Jones Shariah, MSCI Islamic, FTSE Shariah, or DJIM indices

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 12.7%
Liquidity Ratio: 17.5%
Interest Income Ratio: 4.8%
Purification Required: 4.82%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: EXCLUDED
MSCI Islamic: EXCLUDED
DJIM: EXCLUDED
FTSE Shariah: EXCLUDED
Total: 0 of 4
Last Verified: 2025-12-31

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2025
Latest Quarterly Data: Q4 2025
Trend Period: FY 2020 to FY 2025
Data Retrieved: 2026-02-22T12:00:00Z

---
Full interactive report: https://amaly.io/stock/ARDX
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.